1 3

Printify

Tumbler 20oz (Purple Gradient)

Tumbler 20oz (Purple Gradient)

$26.65 USD
$26.65 USD
Sale Sold out
Shipping calculated at checkout.
Size

This tumbler is an excellent choice for daily use to keep 20oz of your favorite beverages hot or cold thanks to the double-wall insulation. Meanwhile, the stainless steel construction provides excellent durability and it's dishwasher safe for added convenience.

.: Materials: stainless steel (body), plastic and rubber (lid)
.: One size: 20oz (0.59 l)
.: Rounded corners
.: Vacuum insulated steel body with a clear push on lid with a rubber gasket
.: Glossy finish

View full details

Recent News

View all
  • Phase 1/2 Trial Launches for Innovative Pancreatic Cancer Immunotherapy

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

  • FDA Approves NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Cancer

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

  • Immunotherapy for Pancreatic Ductal Adenocarcinoma: Barriers and Opportunities

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

1 3
View all